← All indications
Osteosarcoma
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
Subtype terms (2)
More specific conditions that are subtypes of Osteosarcoma in the MeSH hierarchy.
- Osteosarcoma, Juxtacortical
- Sarcoma, Ewing
180 drugs (98 approved, 82 experimental)
Drugs by status
Approved for this indication (3)
Phase 4 trials (4)
Phase 3 trials (25)
- olaparib
- gemcitabine
- naltrexone
- lapatinib
- muramyl tripeptide phosphatidyl ethanolamine
- dinutuximab
- pazopanib
- ifosfamide
- temozolomide
- trabectedin
- cabozantinib
- zoledronic acid
- methotrexate
- triptorelin
- docetaxel
- lobaplatin
- tranexamic acid
- cisplatin
- etoposide
- prednisolone
- sargramostim
- sodium chloride
- interferon alpha-2b
- zkab001
- hs-20093
Phase 2 trials (122)
- metformin
- s-methionine
- azacitidine
- saracatinib
- denosumab
- 5,10-methylene-5,6,7,8-tetrahydrofolate
- ly-3023414
- abemaciclib
- allogeneic natural killer cells
- atezolizumab
- ridaforolimus
- autologous tumor infiltrating lymphocytes
- avelumab
- sorafenib
- bio-11006
- talazoparib
- bvd-523
- irinotecan
- cbl0137
- temsirolimus
- glembatumumab vedotin
- cixutumumab
- silmitasertib
- eflornithine
- selinexor
- durvalumab
- eribulin
- erdafitinib
- fluzoparib
- ganoderma lucidum spore
- +92 more
Phase 1 trials (67)
- simvastatin
- thalidomide
- dexrazoxane
- anlotinib
- plerixafor
- calcium carbonate
- acetylcysteine
- urea
- mkc1106
- cc-115
- cdx-301
- Iopofosine
- eltrombopag
- enoblituzumab
- tacrolimus
- genetically engineered ny-eso-1-specific t lymphocytes
- emd 273063
- imiquimod
- epirubicin
- lexatumumab
- mage-a1, mage-a3, and ny-eso-1 vaccine
- hsv-1716
- prostate specific membrane antigen
- tanespimycin
- dendritic cells
- calcitriol
- gefitinib
- mesna
- adebrelimab
- tumor-pulsed dendritic cells
- +37 more
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (8)
Organization Involved with Phase 3 Indications (26)
- Merck
- Novartis
- Ariad Pharmaceuticals
- Chugai
- Medical Research Council
- National Cancer Institute (NCI)
- National Cancer Institute, France
- University of London
- China Association of Osteosarcoma Chemotherapy
- Chinese Medical Association
- Italian Sarcoma Group
- Johns Hopkins University
- Tata Memorial Hospital
- UNICANCER
- University of Leeds
- University of Michigan
- University of Southern California
- University of Toronto
- Wayne State University
- Peking University
- Leiden University
- Institut Gustave Roussy
- European Organisation for Research and Treatment of Cancer
- Lee's Pharmaceutical
- University of Paris
- Ligue contre le cancer, France
Organization Involved with Phase 2 Indications (85)
- Eisai
- Takeda
- Immunex
- Celgene
- Bristol-Myers Squibb
- Schering-Plough
- AstraZeneca
- Merck Serono
- Eli Lilly
- Genentech
- BTG
- Bayer
- GlaxoSmithKline
- Hengrui Therapeutics, Inc.
- Inex Pharmaceuticals
- Oncolytics Biotech
- Simcere Pharmaceutical Co., Ltd
- Concerto HealthAI
- Epeius Biotechnologies
- Isofol Medical AB
- National Institutes of Health (NIH)
- National Cancer Center, Korea
- Javier Martín Broto, M.D.
- University of Pennsylvania
- Case Western Reserve University
- Centre Leon Berard
- Cornell University
- Florida International University
- Grupo de Apoio ao Adolescente e a Crianca com Cancer
- Grupo Espanol de Investigacion en Sarcomas
- +55 more
Organization Involved with Phase 1 Indications (30)
- Pfizer
- MacroGenics
- Berg, LLC
- Ziopharm
- University of Pittsburgh
- Baylor University
- Cedars-Sinai Medical Center
- Duke University
- Emory University
- University of Washington
- Ohio State University
- University of Louisville
- University of Miami
- South Plains Oncology Consortium
- University of California, San Francisco
- University of Chicago
- University of Colorado, Denver
- Pennsylvania State University
- Methodist Cancer Center, Houston, Texas
- Cellectar, Inc
- University of Wisconsin
- University of Tuebingen
- Children's National Medical Center
- University of Colorado
- Guangdong Xiangxue Precision Medical Technology Co., Ltd
- Reliable Cancer Therapies
- Evan T.J. Dunbar Neuroblastoma Foundation
- OHSU Knight Cancer Institute
- Concentrx Pharmaceuticals, Inc.
- The University of Texas, Dallas
Organization Involved with Other Experimental Indications (4)